CTRI/2011/09/002012已完成2 期
A PHASE II OPEN LABEL, MULTI-CENTER CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF ORAL WCK 2349 (1000 mg BID and 1200 mg BID) IN THE TREATMENT OF COMPLICATED SKIN AND SOFT TISSUE INFECTIONS CAUSED BY GRAM POSITIVE BACTERIA, INCLUDING METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS
Wockhardt Ltd0 个研究点目标入组 120 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Subjects of either sex with 18 -70 years of age.
- •2.Weighing at least 40 kgs
- •3.Clinical diagnosis of cSSTIs as one of the conditions given below
- •(i)infections involving deeper soft tissues such as subcutaneous tissue, fascia and skeletal muscles.
- •(ii)requiring significant surgical intervention such as infected ulcers, burns upto 30%, and deep abscess.
- •(iii)SSTIs with a significant underlying disease state (such as diabetes) that complicates the response to treatment.
- •(iv)superficial infection or abscess in rectal area.
- •4.Suspected or proven Gm +ve bacterial infection as per following criteria:
- •i.Subject receiving antimicrobial therapy in last 72 hrs or on long acting antimicrobial therapy and not responding to antimicrobial therapy for cSSTIs will be considered microbiologically eligible can be enrolled, but to be continued only if the results of tissue culture show growth of gram positive bacteria by central laboratory.
- •ii.Naïve cases with no antimicrobial therapy in last 72 hrs and not on long acting antimicrobial therapy will be enrolled in the study if direct smear or tissue culture growth confirms the presence of the Gm +ve bacteria by gram staining or bacterial identification.
- •4.Subjects with at least one of the following symptoms or sign:
- •(i)Fever, i.e., oral temperature > 38 degree centigrade or 100.4 degree fahrenheit hypothermia i.e., oral temperature <36 degree centigrade or 96.8 degree fahrenheit
- •(iii)Respiratory rate more than 20/minute
- •(iv)Heart rate > 90/minute hypotension (SBP < 90 mm of Hg)
- •(vi)a white blood cell count of >12,000/mm3 or < 4000/ mm3
- •(vii) >10% immature neutrophils regardless of white blood cell count
- •5.Justified need of antimicrobial therapy for cSSTIs with Gm +ve bacteria as judged byinvestigator.
- •6.Subjects, who in the opinion of the PI, are most likely to tolerate oral therapy
- •7.Subject willing to participate in the study and subject or legally acceptable representative willing to give written informed consent.
排除标准
- •1.Subjects not requiring antimicrobial therapy
- •2.Medical conditions leading to difficulty in interpreting response such as superinfected eczema and atopic dermatitis.
- •3.Diagnosed subjects of immunosuppressive conditions like AIDS.
- •4.Subjects receiving or requiring immunosuppressive therapy.
- •5.Subjects with osteomyelitis, septic arthritis, necrotizing fasciitis, gas gangrene and infected prosthetic device or foreign body at the infected site.
- •6.Subjects with endocarditis or meningitis
- •7.Diagnosed subjects of active complicated cardiovascular disease like IHD, CCF,arrhythmias and severe hypertension (Systolic Blood Pressure more than or equal to 160 mmHg OR Diastolic Blood Pressure more than or equal to 100 mmHg)
- •8.Subjects with any of the following abnormality in clinical laboratory parameters
- •a.SGOT (AST) and SGPT (ALT): more than 3 times the upper limit of normal laboratory range, Serum bilirubin and Serum alkaline phosphatase 15% of upper limit of normal laboratory range.
- •b.Blood urea and Serum creatinine 15% of upper limit of normal laboratory range.
- •c.Subjects with uncontrolled diabetes as determined by post prandial plasma or random(casual) plasma glucose 200 mg/dl (11.1 mmol/l)
- •d.Subjects with platelet count 100, 000/ cu.mm.
- •9.Subjects with history of Seizures,
- •10.History of hypersensitivity to fluoroquinolones or quinolones
- •11.Treatment within last 30 days with an investigational new drug.
- •12.Previous treatment with WCK 2349 or WCK 771.
- •13.Pregnant women or nursing mothers and women not practicing effective contraception, including but not limited to implants, injectables, combined oral contraceptives, intrauterine device, sexual abstinence or a vasectomized partner during the trial.
研究者
相似试验
招募中
1 期
A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Patients with Relapsed and/or Refractory CD20-expressing Non-Hodgkin LymphomaRelapsed and/or Refractory CD20-expressing Non-Hodgkin LymphomaMedDRA version: 23.0Level: PTClassification code: 10029601Term: Non-Hodgkin's lymphoma refractory Class: 100000004864CTIS2023-506976-28-00Innate Pharma45
进行中（未招募）
1 期
MK-1439A in treatment-naïve HIV-1 infected subjects with NNRTI transmitted resistance.Human Immunodeficiency Virus-1 infectionMedDRA version: 20.1 Level: PT Classification code 10000807 Term: Acute HIV infection System Organ Class: 10021881 - Infections and infestationsEUCTR2015-003616-20-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.60
进行中（未招募）
1 期
MK-1439A in treatment-naïve HIV-1 infected subjects with NNRTI transmitted resistance.Human Immunodeficiency Virus-1 infectionEUCTR2015-003616-20-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.60
进行中（未招募）
1 期
A Multicenter, Open-Label, Phase 2 Trial to Evaluate the Safety and Activity of Efgartigimod (ARGX-113) in Adult Patients with Primary Immune Thrombocytopenia - ARGX-113-1804Primary Immune ThrombocytopeniaMedDRA version: 20.1Level: LLTClassification code 10074678Term: Primary immune thrombocytopenic purpuraSystem Organ Class: 100000004851EUCTR2019-000361-21-GBArgenx BVBA15
进行中（未招募）
1 期
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Vedotin in Patients with B-Cell Non-Hodgkin LymphomaB-cell non-Hodgkin lymphoma (NHL)MedDRA version: 24.0Level: LLTClassification code 10067070Term: Follicular B-cell non-Hodgkin's lymphomaSystem Organ Class: 100000004864MedDRA version: 20.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 21.0Level: LLTClassification code 10012820Term: Diffuse large B-cell lymphoma NOSSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10012856Term: Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrentSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10023768Term: Large cell immunoblastic lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrentSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10012857Term: Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractorySystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10023769Term: Large cell immunoblastic lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractorySystem Organ Class: 100000004864EUCTR2018-001141-13-ESF. Hoffmann-La Roche Ltd342